share_log
Reuters ·  Nov 7 21:00
Indaptus Therapeutics Presents Encouraging Interim Safety Data From Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment